China’s approval of a first dual BAFF/APRIL therapy in IgA nephropathy signals expanding biologics competition and a shift in kidney disease treatment options.

China’s approval of the first dual BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN) marks a shift in a field where treatment options have historically been limited to supportive care and corticosteroids, with increasing pressure to deliver disease-modifying benefit in kidney disease.

The National Medical Products Administration (NMPA) has approved RemeGen’s telitacicept, marketed as Taiai, for adults with IgAN. The conditional approval makes it the first therapy in its class to target both BAFF and APRIL, two key pathways involved in B-cell survival and antibody production that are implicated in autoimmune kidney damage.

According to GlobalData, the approval adds a differentiated mechanism into a treatment landscape that has been gradually expanding but remains dominated by therapies with partial efficacy and safety trade-offs. Existing options such as corticosteroids can reduce proteinuria but are associated with long-term toxicity risks, while newer targeted agents have shown variable effects on renal outcomes.

Efficacy data supporting the approval included Phase 2 and Phase 3 trial results showing a 58.9% reduction in urinary protein-to-creatinine ratio (UPCR) and a significant decline in estimated glomerular filtration rate (eGFR) compared with ACEI/ARB control groups. Proteinuria reduction remains a key surrogate marker for disease progression in IgAN and is closely tracked across clinical development programmes.

GlobalData Pharma Intelligence Center estimates there were approximately 0.88 million diagnosed prevalent cases of IgAN in China in 2026, highlighting a substantial patient population for emerging therapies. The analysis also notes a growing clinical pipeline, with 19 Chinese companies currently developing IgAN treatments across multiple stages, including five Phase 3 programmes, nine Phase 2 programmes and seven Phase 1 studies.

RemeGen is also expanding its development and commercial strategy beyond China through partnerships, including collaboration with Vor Bio to support further development and potential international market expansion.

Abhishake Peyyeti, pharma analyst at GlobalData, said: “RemeGen strategically expands into the nephrology segment with the approval of Taiai. With its already strong presence in China, RemeGen also partnered with Vor Bio to further develop and market Taiai outside China. The move reflects broader efforts by Chinese biopharma companies to build drugs targeting multiple indications and pursue international partnerships to extend market reach beyond domestic approvals.”

He added: “Telitacicept retains its early-mover advantage in the dual BAFF/APRIL class. However, povetacicept, currently being evaluated in Phase 3 trials, achieved approximately 56% reduction in UPCR from baseline in its Phase 2 studies and could lead to increased competition within the dual class following successful Phase 3 trials and regulatory approvals.”

The competitive outlook for IgAN is therefore expected to intensify as multiple late-stage programmes advance, particularly those targeting proteinuria reduction and long-term renal outcomes rather than short-term biomarker improvement alone.

Overall, the approval reinforces China’s growing role in nephrology innovation while also signalling a more crowded and mechanism-diverse pipeline emerging globally in IgA nephropathy.